|Application ||WB, IHC, E|
|Other Accession||NP_001013675, 61966761|
|Calculated MW||Predicted: 37 kDa; Observed: 48 kDa|
|Application Notes||LRRC26 antibody can be used for detection of LRRC26 by Western blot at 0.5 - 1 µg/ml. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL.|
|Target/Specificity||LRRC26; LRRC26 antibody is human specific.|
|Reconstitution & Storage||LRRC26 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||LRRC26 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Auxiliary protein of the large-conductance, voltage and calcium-activated potassium channel (BK alpha). Required for the conversion of BK alpha channels from a high-voltage to a low- voltage activated channel type in non-excitable cells. These are characterized by negative membrane voltages and constant low levels of calcium.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein. Cytoplasm, cytoskeleton. Note=Localizes to the cytoplasm when expressed at high levels.|
|Tissue Location||Isoform 1 is expressed highly in normal prostate and salivary gland, very weakly in colon, pancreas, and intestine, and not at all in other tissues. Isoform 1 is expressed highly in many cancer cell lines and in breast cancer, pancreatic cancer and colon cancer. Isoform 2 is expressed in cancer cell lines.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The LRRC26 protein was initially identified as a cytokeratin-associated protein whose expression was elevated in multiple cancer cell lines and cancer specimens as well in normal prostate and salivary gland tissues (1). LRRC26 was later found to negatively regulate the NF-kappaB activation and suppresses tumor growth and metastasis (2). LRRC26 can also act to selectively alter the efficacy of large conductance calcium-activated K (BK) channels (3).
Egland KA, Liu XF, Squires S, et al. High expression of a cytokeratin-associated protein in many cancers. Proc. Natl. Acad. Sci. USA 2006; 103:5929-34.
Liu XF, Xiang L, Zhang Y, et al. CAPC negatively regulates NF-?B activation and suppresses tumor growth and metastasis. Oncogene 2012; 31:1673-82.
Almassy J and Begenisich T. The LRRC26 protein selectively alters the efficacy of BK channel activators. Mol. Pharmacol. 2012; 81:21-30.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.